Week Ending October 10, 2022

Hepatitis C Rash: Skin Symptoms and Signs of Progression
“Rashes and other skin symptoms are common with hepatitis C, a liver infection caused by the hepatitis C virus (HCV). They can occur in the initial acute infection, as side effects of hepatitis C medications, or as complications from later-stage liver disease, such as cirrhosis (liver scarring) or liver cancer.”

CDC Reports Shift in Hepatitis A Infections
“Most hepatitis A infections in recent years have been linked to drug use or homelessness, according to research published by the Centers for Disease Control and Prevention (CDC) Morbidity and Mortality Weekly Report.”

Significant antiviral activity of bulevirtide for treatment of chronic hepatitis D infection
“Between 10 and 20 million people worldwide are infected with hepatitis D virus (HDV). HDV infection is always associated with hepatitis B virus infection. So far there has been no satisfactory therapeutic option for this most severe form of chronic viral hepatitis.”

Hepatitis C Symptoms: What They Are And How They Differ From Hepatitis A And B
“When it comes to hepatitis, the liver disease that disproportionately affects Black people can exhibit similar symptoms regardless of which of its variations one is inflicted with.”

Liver Disease Risk Remains for HCV Patients With Bleeding Disorders
“Despite the ability to cure hepatitis C virus (HCV) infections with direct-acting antivirals (DAA), there remains a risk of liver-related complications for patients with inherited bleeding disorders after the HCV is cured.”

Single-tablet DAA in a patient with chronic hepatitis C and decompensated liver cirrhosis
“A 64-year-old Chinese woman with a history of intravenous (IV) drug use in her 20s and 30s was first di­agnosed with chronic hepatitis C (CHC) in 2010. The patient was as­ymptomatic, and transient elastog­raphy (FibroScan) revealed a fibro­sis score of 4.8 kPa, indicating no evidence of fibrosis. Her prior health status was otherwise good, with no long-term use of prescription drugs and no comorbidities, including hep­atitis B or HIV coinfection.”

Clinical Trial Results Allude to New Options for Patients With HCC
“In an interview with Targeted Oncology, Ghassan K. Abou-Alfa, MD, discussed 3 late breaking abstracts in the hepatocellular carcinoma space currently influencing the field.”

Social Demographics Help Explain Unscreened HCV Individuals
“In Philadelphia, 28% of the patient population was unscreened, with the factors associated with lower risks of being unscreened generally associated with a higher HCV positivity rate.”

The Age, Gamma-Glutamyl Transpeptidase and Platelet Index: A Novel Noninvasive Model for Predicting Hepatocellular Carcinoma in Patients with Hepatitis B Virus-Related Liver Cirrhosis
“High incidence of hepatocellular carcinoma (HCC) exists in patients with liver cirrhosis (LC), but the predictive accuracy of noninvasive scoring systems (NSSs) is yet to be elucidated. The present study aimed to evaluate the predictive ability of fibrosis-4 (FIB-4), aminotransferase-to-platelet ratio index (APRI), and gamma-glutamyl transpeptidase to platelet ratio (GPR) in patients with LC, and to establish a new model with more accuracy.”